GlobeNewsWire
23 Jan 2026, 13:11 UTC · 34w ago
Verdict
Headline takes no side. We score ACRV +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Acrivon Therapeutics will present interim clinical data from its registrational-intent Phase 2b study of ACR-368 for endometrial cancer at the ESGO Annual Congress (Feb 26-28, 2026).
So whatClinical data presentations from registrational-intent trials are primary catalysts for biotech valuations and can lead to significant price volatility.
More positive than 92% of claims this week
The lead candidate ACR-368 has received FDA Fast Track designation and Breakthrough Device designation for its associated OncoSignature assay.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 64% of claims this week
The company is advancing a second clinical-stage asset, ACR-2316, which has shown initial clinical activity in endometrial cancer, SCLC, and sqNSCLC in Phase 1 trials.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company announced a high-profile presentation of promising interim clinical data for its lead drug candidate at a major medical congress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
+1.5%
Price agrees with the score
$2.06 vs $2.03 close before publication (Jan 22) · not market-adjusted
ACRV chart →
